Año 2024 / Volumen 116 / Número 10
Editorial
Lights and shadows in the new definition of steatotic liver disease

523-525

DOI: 10.17235/reed.2024.10696/2024

Paula Iruzubieta, María Teresa Arias-Loste, Javier Crespo,

Resumen
The presence of marked hepatic steatosis in patients with high alcohol consumption was first described in 1836 by Addison et al.1 Many years later, in 1980, Ludwig and colleagues described a histological picture very similar to that seen in patients with alcoholic hepatitis but who did not consume alcohol, coining the term non-alcoholic steatohepatitis (NASH).2 In recent years, the terminology used to describe conditions related to hepatic steatosis has undergone significant evolution. In 2020, Eslam et al.3 subsequently modified it to MAFLD (Metabolic Associated Fatty Liver Disease) to better reflect its association with metabolic dysfunction, a nomenclature that, from the beginning, generated some reluctance due to the absence of clear international consensus.
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Addison T. Observations on fatty degeneration of the liver. Guys Hosp Rep. 1836.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-438. http://www.ncbi.nlm.nih.gov/pubmed/7382552. Accessed December 26, 2016.
3. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209. doi:10.1016/j.jhep.2020.03.039
4. Rinella ME, Lazarus J V., Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520
5. Song SJ, Lai JC-T, Wong GL-H, Wong VW-S, Yip TC-F. Can we use old NAFLD data under the new MASLD definition? J Hepatol. August 2023. doi:10.1016/J.JHEP.2023.07.021
6. De A, Bhagat N, Mehta M, Taneja S, Duseja A. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD. J Hepatol. 2024;80(2):e61-e62. doi:10.1016/J.JHEP.2023.07.031
7. Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80(2):e76-e77. doi:10.1016/J.JHEP.2023.08.026
8. Lee CM, Yoon EL, Kim M, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology. 2024;79(6):1393-1400. doi:10.1097/HEP.0000000000000664
9. Iruzubieta P, Santos-Laso A, Arias-Loste MT, Calleja JL, Crespo J. Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology in different clinical settings. J Hepatol. 2024;80(3):e121-e123. doi:10.1016/J.JHEP.2023.10.026
10. Loomba R, Wong VWS. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024;59(2):150-156. doi:10.1111/APT.17846
11. Marti-Aguado D, Calleja JL, Vilar-Gomez E, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol. July 2024. doi:10.1016/J.JHEP.2024.06.036
12. Alboraie M, Fouad Y, Eslam M. Letter to the Editor: MAFLD versus MASLD-Which is more appropriate from a global perspective? Hepatology. May 2024. doi:10.1097/HEP.0000000000000886
13. Pan Z, Shiha G, Esmat G, Méndez-Sánchez N, Eslam M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int. 2024;44(7):1567-1574. doi:10.1111/LIV.15931
14. Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;43(11):2425-2433. doi:10.1111/LIV.15695
15. Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. lancet Gastroenterol Hepatol. 2021;6(7):578-588. doi:10.1016/S2468-1253(21)00020-0
16. Peterson D, Keeley JW. Syndrome, Disorder, and Disease. Encycl Clin Psychol. January 2015:1-4. doi:10.1002/9781118625392.WBECP154
Artículos relacionados
Instrucciones para citar
Iruzubieta P, Arias-Loste M, Crespo J. Lights and shadows in the new definition of steatotic liver disease. 10696/2024


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 2035 veces.
Este artículo ha sido descargado 127 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 31/07/2024

Aceptado: 01/08/2024

Prepublicado: 05/09/2024

Publicado: 09/10/2024

Tiempo de prepublicación: 36 días

Tiempo de edición del artículo: 70 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2025 y Creative Commons. Revista Española de Enfermedades Digestivas